Blood-Brain Barrier Disruption (BBBD) for Liquid Biopsy in Subjects With GlioBlastoma Brain Tumors

NACompletedINTERVENTIONAL
Enrollment

71

Participants

Timeline

Start Date

August 8, 2022

Primary Completion Date

February 21, 2025

Study Completion Date

March 5, 2025

Conditions
GlioblastomaGliomaLiquid Biopsy
Interventions
DEVICE

Focused Ultrasound (Exablate Model 4000)

BBB opening via Exablate Type 2 system with microbubble resonators and drawing blood before and after opening

Trial Locations (17)

10016

NYU Grossman School of Medicine, New York

21201

University of Maryland, Baltimore & The University of Maryland Medical System, Baltimore

21218

Johns Hopkins University, Baltimore

26506

West Virginia University Rockefeller Neuroscience Center, Morgantown

27516

University of North Carolina, Chapel Hill

27710

Duke University, Durham

32608

UF Health Shands Hospital, Gainesville

33176

Miami Cancer Institute at Baptist Health, Miami

33606

Tampa General Hospital, Tampa

33612

Moffitt Cancer Center, Tampa

55905

Mayo Clinic, Rochester

75390

University of Texas, Southwestern, Dallas

77030

University of Texas MD Anderson Cancer Center, Houston

90095

University of California, Los Angeles, Los Angeles

92618

Hoag Memorial Hospital Presbyterian, Newport Beach

94107

University of California San Francisco, San Francisco

M4N 3M5

Sunnybrook Research Institute, Toronto

Sponsors

Lead Sponsor

All Listed Sponsors
lead

InSightec

INDUSTRY

NCT05383872 - Blood-Brain Barrier Disruption (BBBD) for Liquid Biopsy in Subjects With GlioBlastoma Brain Tumors | Biotech Hunter | Biotech Hunter